(:OSMT)

Jan 19, 2022 11:38 am ET
UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fou
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“OSMT” or the “Company”), a specialty pharmaceutical company, announced today that the Company has changed its name to RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL”). This rebranding reflects RVL’s...
Jan 19, 2022 06:50 am ET
Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quart
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“OSMT” or the “Company”), a specialty pharmaceutical company, announced today that the Company has changed its name to RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL”). This rebranding reflects RVL’s...
Jan 18, 2022 06:50 am ET
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer and James “JD” Schaub, Chief Operating Officer, will host a video webcast to...
Jan 06, 2022 08:55 am ET
Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and other key speakers, will...
Dec 23, 2021 09:45 am ET
Thinking about buying stock in Allakos, 22nd Century Group, Osmotica Pharmaceuticals, Banco Santander SA, or Opko Health?
NEW YORK, Dec. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALLK, XXII, OSMT, SAN, and OPK.
Dec 20, 2021 04:05 pm ET
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief...
Nov 15, 2021 04:05 pm ET
Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced business highlights and financial results for the three months ended September 30, 2021. “With the sale of our legacy...
Nov 15, 2021 06:50 am ET
Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief...
Nov 11, 2021 07:30 pm ET
Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, after the close of...
Oct 13, 2021 04:45 pm ET
Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced underwritten public offering of 14,000,000 ordinary shares...
Oct 07, 2021 10:45 am ET
Thinking about buying stock in Camber Energy, Bit Digital, Brickell Biotech, Osmotica Pharmaceuticals, or SmileDirectClub?
NEW YORK, Oct. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CEI, BTBT, BBI, OSMT, and SDC.
Oct 07, 2021 09:04 am ET
Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a note purchase agreement for up to $100 million of senior secured notes with funds managed by...
Oct 07, 2021 12:31 am ET
Osmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public Offering
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and...
Oct 06, 2021 04:26 pm ET
Osmotica Pharmaceuticals plc Announces Proposed Underwritten Public Offering
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its ordinary shares and warrants to purchase its ordinary...
Sep 22, 2021 05:00 pm ET
Osmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief...
Sep 02, 2021 05:00 pm ET
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at...
Aug 30, 2021 06:50 am ET
Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has closed the previously announced sale of its legacy business, including certain of the Company’s US...
Aug 16, 2021 04:05 pm ET
Osmotica Pharmaceuticals plc Reports Second Quarter 2021 Results and Provides Business Update
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months ended June 30, 2021. “With the announcement of...
Aug 12, 2021 05:30 pm ET
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at...
Aug 11, 2021 07:00 pm ET
Osmotica Pharmaceuticals plc to Provide Second Quarter 2021 Business and Financial Update on August 16, 2021
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 second quarter financial results on Monday, August 16, 2021, after the...
Jun 30, 2021 07:15 am ET
Osmotica Subsidiary RVL Pharmaceuticals, Focused on Eye Care and Ocular Aesthetics, Strengthens and Expands Leadership Team
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that J. Aaron Green will join the leadership team of RVL Pharmaceuticals, Inc. (“RVL”), the Company’s wholly...
Jun 25, 2021 09:31 am ET
Thinking about buying stock in Osmotica Pharmaceuticals, Property Solutions Acquisition, Sio Gene Therapies, Clearside Biomedical, or Sorrento Therapeutics?
NEW YORK, June 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OSMT, PSAC, SIOX, CLSD, and SRNE.
Jun 25, 2021 06:50 am ET
Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC
Osmotica Pharmaceuticals, plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that it has entered into a definitive Purchase and Sale Agreement with Alora Pharmaceuticals, LLC (“Alora”)...
Jun 18, 2021 06:50 am ET
Osmotica Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced results of the Company’s Annual General Meeting. At the Annual General Meeting of the Company held on June 17,...
May 25, 2021 05:30 pm ET
Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Healthcare Conference 2021
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn,...
May 13, 2021 04:05 pm ET
Osmotica Pharmaceuticals plc Reports First Quarter 2021 Results and Provides Business Update
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months ended March 31, 2021. “The early momentum we...
May 12, 2021 04:30 pm ET
Osmotica Pharmaceuticals plc to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the...
May 10, 2021 08:30 am ET
RVL Pharmaceuticals Upneeq® Wins 2021 MedTech Breakthrough Award
RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), a fully integrated biopharmaceutical company, today announced that its Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been...
May 07, 2021 04:05 pm ET
Osmotica Pharmaceuticals plc to Provide First Quarter 2021 Business and Financial Update on May 13, 2021
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2021 first quarter financial results on Thursday, May 13, 2021, after the...
Apr 24, 2021 10:36 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Osmotica Pharmaceuticals plc - OSMT
Pomerantz LLP is investigating claims on behalf of investors of  Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (NASDAQ: OSMT).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext....
Mar 30, 2021 04:05 pm ET
Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months and full year ended December 31, 2020....
Mar 24, 2021 04:30 pm ET
Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2020 Business and Financial Update on March 30, 2021
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 30,...
Mar 03, 2021 05:00 pm ET
Osmotica to Present at Barclays Global Healthcare Conference 2021
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the...
Feb 18, 2021 04:30 pm ET
Osmotica to Present at 10th Annual SVB Leerink Global Healthcare Conference
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the...
Feb 01, 2021 04:30 pm ET
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
Ap9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i)AMENDMENT The Form 8.1(a) dealings disclosure announcement made on January 27, 2020 contained a typographical error in that it referred to dealings in 'relevant securities' by Gregory L. Cowan,...
Jan 27, 2021 05:05 pm ET
DIRECTOR DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
fAp9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i) IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES,...
Jan 27, 2021 05:05 pm ET
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
Ap9 APPENDIX 3 DISCLOSURE FORMS FORM 8.1(a)&(b)(i) IRISH TAKEOVER PANEL DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013...
Jan 27, 2021 05:00 pm ET
Rule 2.10 Announcement
In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the Irish Takeover Rules), Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (Osmotica or the Company) confirms that, as of the close of business on January 27,...
Dec 29, 2020 05:15 pm ET
Osmotica Pharmaceuticals plc Receives Complete Response Letter from U.S. Food and Drug Administration for Arbaclofen Extended Release Tablets
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) regarding the Company's New Drug Application (“NDA”) seeking...
Dec 02, 2020 07:01 am ET
Osmotica Pharmaceuticals plc Announces Agreement to Settle Patent Litigation with Adamas
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that its subsidiary Osmotica Pharmaceutical US LLC has entered into an agreement to settle its ongoing patent...
Nov 18, 2020 08:15 am ET
RVL Pharmaceuticals, Inc. Strengthens Leadership Team as Commercial Launch of Upneeq® Expands
RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), announced the addition of Dr. Raymond Douglas, M.D. to its leadership team as Global Head, Scientific Affairs. "We are thrilled to have Dr....
Nov 12, 2020 04:30 pm ET
Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual London Healthcare Conference
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the...
Nov 10, 2020 04:05 pm ET
Osmotica Pharmaceuticals plc Reports Third Quarter 2020 Results and Provides Business Updates
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months ended September 30, 2020. “With the...
Nov 05, 2020 05:30 pm ET
Osmotica Pharmaceuticals plc to Provide Third Quarter 2020 Business and Financial Update on November 10, 2020
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 third quarter financial results on Tuesday, November 10, 2020, after the...
Oct 01, 2020 01:32 pm ET
JAMA Ophthalmology Publishes Pooled Analysis of Data from two Phase 3 Clinical Trials of Upneeq™ (oxymetazoline hydrochloride, 0.1% solution) for Acquired Ptosis
RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (Osmotica), today announced that JAMA Ophthalmology has published pooled analysis of data from two Phase 3 clinical trials of Upneeq™ (oxymetazoline...
Sep 02, 2020 04:30 pm ET
Osmotica to Present at 2020 Wells Fargo Virtual Healthcare Conference
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at...
Aug 11, 2020 04:05 pm ET
Osmotica Pharmaceuticals plc Reports Second Quarter 2020 Results and Provides Business Updates
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months ended June 30, 2020. “The past several months...
Aug 06, 2020 08:00 pm ET
Osmotica Pharmaceuticals plc to Provide Second Quarter 2020 Business and Financial Update and Presentation on Upneeq™ on August 11, 2020
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 second quarter financial results on Tuesday, August 11, 2020, after the...
Jul 28, 2020 06:50 am ET
Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired Blepharoptosis
Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (hereinafter, Osmotica), announced today an exclusive license agreement covering the development,...
Jul 20, 2020 06:50 am ET
Osmotica Pharmaceutical US LLC Announces FDA User Fee Goal Date of December 29, 2020 for Arbaclofen Extended Release Tablets
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) through its subsidiary Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA)...
Jul 13, 2020 09:52 pm ET
Osmotica Announces Pricing of Public Offering of Ordinary Shares
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the pricing of its previously announced public offering of 5,000,000 ordinary shares at a price to the public...
Jul 13, 2020 04:15 pm ET
Osmotica Announces Proposed Public Offering of Ordinary Shares
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the commencement of a proposed public offering of 5,000,000 ordinary shares. All of the shares will be offered...
Jul 09, 2020 06:50 am ET
Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved Upneeq (oxymetazoline hydrochloride ophthalmic...
Jun 30, 2020 06:50 am ET
Osmotica Pharmaceuticals US LLC Submits Amended NDA for Arbaclofen Extended Release Tablets to U.S. Food and Drug Administration
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) through its subsidiary Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that the Company has resubmitted its New Drug Application...
Jun 16, 2020 04:30 pm ET
Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Optical Health Summit
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at...
May 27, 2020 04:30 pm ET
Osmotica Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting
BRIDGEWATER, N.J., May 27, 2020 /PRNewswire/ -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) ("Osmotica" or the "Company"), a fully integrated biopharmaceutical company, today announced results of the Company's Annual General Meeting.  
May 26, 2020 04:30 pm ET
Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual Healthcare Conference
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the...
May 13, 2020 05:08 pm ET
Osmotica Pharmaceuticals plc to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the...
May 12, 2020 04:05 pm ET
Osmotica Pharmaceuticals plc Reports First Quarter 2020 Results and Provides Business Updates
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months ended March 31, 2020. “Despite the ongoing...
May 08, 2020 01:30 pm ET
Osmotica Pharmaceuticals plc to Provide First Quarter 2020 Business and Financial Update on May 12, 2020
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2020 first quarter financial results on Tuesday, May 12, 2020, after the...
Mar 18, 2020 04:05 pm ET
Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2019 Results and Provides Business Updates
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months and full year ended December 31, 2019. “With...
Mar 12, 2020 06:00 pm ET
Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2019 Business and Financial Update on March 18, 2020
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the Company will release its 2019 fourth quarter and full year financial results on Wednesday, March 18,...
Mar 03, 2020 06:50 am ET
Osmotica to Present at Barclays Global Healthcare Conference 2020
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the...
Feb 18, 2020 05:00 pm ET
Osmotica to Present at 9th Annual SVB Leerink Global Healthcare Conference
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the...
Jan 08, 2020 08:40 pm ET
Osmotica Announces Pricing of Public Offering of Ordinary Shares
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the pricing of its public offering of 6,000,000 ordinary shares at a price to the public of $5.00 per share....
Jan 06, 2020 06:50 am ET
Osmotica Announces Proposed Public Offering of Ordinary Shares
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the commencement of a proposed public offering of 6,000,000 ordinary shares. All of the shares will be offered...
Nov 20, 2019 06:50 am ET
Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Acceptance of New Drug Application by FDA for RVL-1201 (Oxymetazoline Hydrochloride Ophthalmic Solution, 0.1%) for Acquired Blepharoptosis
Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company) today announced that the Company received notification that the New Drug...
Nov 14, 2019 04:05 pm ET
Osmotica Pharmaceuticals plc Reports Third Quarter 2019 Results
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the quarter ended September 30, 2019. “We are pleased with the...
Nov 08, 2019 01:00 pm ET
Osmotica Pharmaceuticals plc to Provide Third Quarter 2019 Business and Financial Update on November 15, 2019
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2019 third quarter financial results on Thursday, November 14, 2019, after...
Sep 27, 2019 06:50 am ET
Osmotica Pharmaceuticals plc Appoints Industry Executive Michael J. DeBiasi to Board of Directors
Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced the appointment of Michael J. DeBiasi to the Company’s Board of Directors, effective as of October 1, 2019....
Sep 18, 2019 06:50 am ET
Vertical Pharmaceuticals LLC, an Osmotica company, Announces Presentation of Phase III RVL-1201 Clinical Trial Data in Patients with Acquired Blepharoptosis (droopy eyelid)
Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company) today announced that Phase III clinical trial results for RVL-1201...
Sep 17, 2019 06:50 am ET
Vertical Pharmaceuticals, LLC, an Osmotica Company, Announces Submission of New Drug Application for RVL-1201
Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company), today announced the submission of a New Drug Application (NDA) to the U.S. Food...
Sep 04, 2019 06:50 am ET
Osmotica Pharmaceuticals plc Announces Results of Extraordinary General Meeting
BRIDGEWATER, N.J., Sept. 4, 2019 /PRNewswire/ -- Osmotica Pharmaceuticals plc ("Osmotica" or the "Company") (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced results of the Company's Extraordinary General Meeting.
Aug 28, 2019 04:30 pm ET
Osmotica Pharmaceuticals plc to Present at 2019 Wells Fargo Healthcare Conference
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Andrew Einhorn, Chief Financial Officer, will present at the 2019 Wells Fargo Healthcare Conference as...
Aug 08, 2019 04:05 pm ET
Osmotica Pharmaceuticals plc Reports Second Quarter 2019 Results
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the quarter ended June 30, 2019. “During the second quarter,...
Aug 01, 2019 04:30 pm ET
Osmotica Pharmaceuticals plc to Provide Second Quarter 2019 Business and Financial Update on August 8, 2019
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2019 second quarter financial results on Thursday, August 8, 2019, after the...
Jul 02, 2019 09:03 pm ET
Shareholder Rights Law Firm Johnson Fistel Launches Investigations
SAN DIEGO, July 2, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims for violations of federal law against the following companies that recently issued stock in connection with an initial public offering ("IPO"):
May 30, 2019 04:30 pm ET
Osmotica Pharmaceuticals plc to Present at Jefferies 2019 Global Healthcare Conference
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn,...
May 14, 2019 04:30 pm ET
Osmotica Pharmaceuticals plc to Present at 2019 RBC Capital Markets Global Healthcare Conference
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn,...
May 09, 2019 04:01 pm ET
Osmotica Pharmaceuticals plc Reports First Quarter 2019 Financial Results and Highlights Pipeline and Business Progress
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months ended March 31, 2019. “During the first...
May 06, 2019 04:30 pm ET
Osmotica Pharmaceuticals plc Announces Positive Topline Results of Phase III Clinical Trials of RVL-1201 (“RVL”) for Acquired Blepharoptosis (ptosis or droopy eyelid)
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced positive topline results of its second Phase III efficacy and safety clinical trial (Study 202) of RVL...
May 02, 2019 05:00 pm ET
Osmotica Pharmaceuticals plc to Provide First Quarter 2019 Business and Financial Update on May 9, 2019
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2019 first quarter financial results on Thursday, May 9, 2019, after the...
Apr 12, 2019 12:45 pm ET
Robbins Arroyo LLP is Investigating the Officers and Directors of Osmotica Pharmaceuticals plc (OSMT) on Behalf of Shareholders
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) violated federal securities law. Osmotica is a biopharmaceutical company focused on developing and commercializing specialty products.
Apr 11, 2019 12:05 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Osmotica Pharmaceuticals plc investors (“Osmotica” or the “Company”) (NASDAQ: OSMT) concerning the Company and its officers’ possible violations of federal securities laws.
Apr 08, 2019 03:06 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors (OSMT)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (NASDAQ: OSMT) investors concerning the Company and its officers’ possible violations of federal securities laws.
Apr 02, 2019 02:21 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors (OSMT)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (NASDAQ: OSMT) investors concerning the Company and its officers’ possible violations of federal securities laws.
Mar 29, 2019 02:17 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Osmotica Pharmaceuticals plc Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Osmotica Pharmaceuticals plc investors (“Osmotica” or the “Company”) (NASDAQ: OSMT) concerning the Company and its officers’ possible violations of federal securities laws.
Mar 28, 2019 11:54 am ET
SHAREHOLDER ALERT: Investigation of Osmotica Announced by Holzer & Holzer, LLC
Holzer & Holzer, LLC is investigating whether certain statements made by Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (NASDAQ: OSMT) complied with federal securities laws. On March 27, 2019, after the markets closed, Osmotica announced preliminary results for a second Phase 3 clinical trial of arbaclofen extended-release tablets that failed to beat placebo as measured by the Clinical Global Impression of Change. The price of Osmotica stock declined following this news.
Mar 27, 2019 04:05 pm ET
Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced business highlights and financial results for the three months and full year ended December 31, 2018. “This...
Mar 21, 2019 06:02 pm ET
Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2018 Business and Financial Update on March 27, 2019
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2018 fourth quarter and full year financial results on Wednesday, March 27,...
Dec 27, 2018 07:00 am ET
Osmotica Pharmaceuticals Appoints Seasoned Financial Executive Gregory Cowan to Board of Directors and Audit Committee
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Gregory Cowan, a seasoned financial executive with almost 40 years of  experience will join the Company’s...
Dec 03, 2018 04:30 pm ET
Osmotica Pharmaceuticals to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the...
Nov 08, 2018 04:01 pm ET
Osmotica Pharmaceuticals plc Reports Third Quarter 2018 Results
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced financial results for the three and nine months ended September 30, 2018. Recent Business and Financial...
Nov 05, 2018 07:00 am ET
Osmotica Pharmaceuticals plc to Discuss Third Quarter 2018 Financial Results on November 8, 2018
Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (Nasdaq: OSMT), a fully integrated biopharmaceutical company, today announced that the Company will release its 2018 third quarter financial results on Thursday, November 8, 2018, after the...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.